Mirna Therapeutics Inc. (NASDAQ:MIRN) had its price target lowered by analysts at Citigroup Inc. from $4.50 to $2.00 in a report released on Thursday, StockTargetPrices.com reports. The firm currently has a “neutral” rating on the stock.

A number of other analysts have also commented on MIRN. Oppenheimer Holdings Inc. lowered shares of Mirna Therapeutics from an “outperform” rating to a “market perform” rating in a report on Wednesday. Leerink Swann lowered shares of Mirna Therapeutics from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $10.00 to $4.00 in a report on Monday, August 15th. Cantor Fitzgerald lowered shares of Mirna Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday. Zacks Investment Research lowered shares of Mirna Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, August 18th. Finally, HC Wainwright assumed coverage on shares of Mirna Therapeutics in a report on Monday, September 12th. They set a “buy” rating and a $6.00 target price for the company. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $6.96.

Mirna Therapeutics (NASDAQ:MIRN) traded up 1.00% during trading on Thursday, hitting $2.02. 25,485 shares of the stock were exchanged. The stock has a 50 day moving average price of $3.11 and a 200-day moving average price of $4.10. The firm’s market capitalization is $42.09 million. Mirna Therapeutics has a 12-month low of $1.82 and a 12-month high of $11.01.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/mirna-therapeutics-inc-mirn-price-target-lowered-to-2-00-at-citigroup-inc.html

About Mirna Therapeutics

Mirna Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response.

5 Day Chart for NASDAQ:MIRN

Stock Target Prices

Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.